Decei Pharma announces the latest research results of Celiniso in the treatment of relapsed and refractory multiple myeloma at the 2021 ASCO and EHA conferences｜Press Release

-The results of the trial showed that the ORR of Sd regimen was 33.
3% in patients exposed to the three types of drugs, and the ORR was 44.
4% in patients who had previously received CAR-T therapy-Celiniso is currently the only one in the commercialization stage XPO1 Inhibitors-Shanghai and Hong Kong, China, June 4, 2021-Deqi Pharmaceutical Co.
, Ltd.
(abbreviated as "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
HK) dedicated to the development and commercialization of innovative tumor therapies ) Announced that the company announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting and the 2021 European Association of Hematology (EHA) conference that Celiniso and dexamethasone (Sd regimen) are used to treat relapsed and refractory multiple bone marrow in China The latest findings of the Phase II MARCH trial in patients with tumors.

A planned analysis was conducted for the first 60 patients receiving treatment.
The median follow-up time was 9.
5 months.
The results showed that the objective response rate (ORR) was 26.
7%.

In addition, the test results showed that the ORR of Sd regimen was 33.
3% in patients exposed to three types of drugs (immunomodulators, proteasome inhibitors and CD38 monoclonal antibodies), and the ORR reached 44.
4 in patients who had previously received CAR-T therapy.
%.

Among Chinese multiple myeloma patients who have received immunomodulators (IMiDs) and proteasome inhibitors (PIs) and still relapse, the data from the MARCH trial and the STORM trial (this trial data once supported the FDA to accelerate the approval of Celinisole) Consistent, further proves the effectiveness and safety of the Sd scheme.

Celiniso is the world's first XPO1 inhibitor for the treatment of relapsed and refractory multiple myeloma and diffuse large B-cell tumors.
Five treatment options have been included in the National Comprehensive Cancer Network (NCCN®) guidelines and four The treatment plan is included in the Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines.

Deck Pharmaceuticals has submitted Celiniso's New Drug Marketing Application (NDA) in 5 Asia-Pacific markets, and it is expected to be approved in the fourth quarter of 2021 and the first quarter of 2022.

2021 ASCO annual meeting to obtain the abstract online: https://meetinglibrary.
asco.
org/record/195519/abstract abstract title: China MARCH study results: ATG-010 (celinisol) combined with low-dose dexamethasone treatment Efficacy and safety of immunomodulators and proteasome inhibitors in patients with multiple myeloma refractory to treatment.
Abstract number: e200022021 EHA annual meeting.
Abstract available online: https://library.
ehaweb.
org/eha/2021/eha2021- virtual-congress/324343/weijun.
fu.
phase.
2.
march.
study.
of.
oral.
atg-010.
plus.
low.
dose.
dexamethasone.
in.
html Abstract Title: China MARCH Research Results: ATG-010 Linnisole) combined with low-dose dexamethasone in the treatment of multiple myeloma patients who have been refractory to immunomodulators and proteasome inhibitors.
Abstract No.
: PB1670 "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
HK) is a leading R&D-driven biopharmaceutical company dedicated to providing the most advanced therapies for patients in Asia-Pacific and even the world, treating tumors and other life-threatening diseases .

Since its official operation in 2017, Deqi Pharmaceuticals has established a rich product pipeline that extends from pre-clinical to clinical stages through cooperative introduction and independent research and development.

At present, Deqi Pharma has obtained 15 clinical approval documents (IND) in multiple Asia-Pacific markets and submitted 5 new drug listing applications (NDA).

With the vision of "Doctors have no boundaries, innovation and sustainability", Deqi Pharmaceuticals will focus on the early R&D, clinical research, drug production and commercialization of the first and best-in-class therapies to solve urgent clinical needs.

Forward-looking statements The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article.

Except as required by law, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether new information, future events or other circumstances appear.

Please read this article carefully and understand that our actual future results or performance may differ materially from expectations.

Statements or references in this article regarding the intentions of any directors or the company were made on the date of publication of this article.

Any such intentions may change due to future development.

*The STORM trial is a multi-center, single-arm, open-label Phase IIb trial initiated by Karyopharm to evaluate the efficacy of Celinisol combined with dexamethasone in multi-line relapsed and refractory multiple myeloma.